Time filter

Source Type

Zhu W.-Z.,Beijing Cancer Hospital & Institute | Fan Z.-Y.,Beijing Cancer Hospital & Institute
Chinese Journal of New Drugs

Objective: To evaluate the clinical efficacy and safety of oxycodone hydrochloride in the anesthesia for percutaneous radiofrequency ablation (PRFA) of liver tumor. Methods: Totally 40 ASA I~II patients with liver tumor aged 40~70 years scheduled for percutaneous radiofrequency ablation (RFA) under intravenous anesthesia were randomly divided into two groups (n=20 in each group). They were treated with intravenous injection of either fentanyl (1 μg·kg-1+propofol 1.5 mg·kg-1) or oxycodone hydrochloride (0.1 mg·kg-1+propofol 1.5 mg·kg-1) three minutes before the therapy. MAP, HR and SPO2 were monitored and recorded before, during and after RFA. The analgesic effect and the incidence of side effect in each group were observed, and the operation time, awake time and the total quantity of propofol were recorded. Results: There were no statistical significance between two groups in the operation time, analgesic effect, and total quantity of propofol. The awake time and the incidence of side-effect in oxycodone hydrochloride group was significantly less than those in fentanyl group (P<0.05). Compared with fentanyl group, the values of MAP, HR and SPO2 in oxycodone hydrochloride group fluctuated more slightly (P<0.05). Conclusion: Intravenous oxycodone hydrochloride for percutaneous radiofrequency ablation is safe and effective. © 2016, Chinese Journal of New Drugs Co. Ltd. All right reserved. Source

Discover hidden collaborations